Last reviewed · How we verify

Track A

ATS Clinical Research · FDA-approved active Small molecule

Track A is a medication that works by inhibiting the reuptake of certain neurotransmitters.

Track A is a medication that works by inhibiting the reuptake of certain neurotransmitters. Used for Major depressive disorder, Obsessive-compulsive disorder, Panic disorder.

At a glance

Generic nameTrack A
Also known asActive study drug, Bimatoprost 0.03% solution
SponsorATS Clinical Research
Drug classSelective serotonin reuptake inhibitor
TargetSerotonin transporter
ModalitySmall molecule
Therapeutic areaPsychiatry
PhaseFDA-approved

Mechanism of action

This leads to increased levels of these neurotransmitters in the brain, which can help improve mood and reduce symptoms of depression. The exact mechanism of action is not fully understood, but it is thought to involve the inhibition of the serotonin transporter.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: